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Abstract Staphylococcus aureusmight amplify symptoms in
chronic inflammatory skin diseases. This study evaluates skin
and mucosal colonization with S. aureus in patients with pso-
riasis, acne and rosacea. A systematic literature search was
conducted. Both odds ratios (OR) for colonization in patients
versus controls and the prevalence of colonization in patients
are reported. Fifteen articles about psoriasis and 13 about acne
(12 having a control group) were included. No study in rosa-
cea met our inclusion criteria. For psoriasis, one study out of
three controlled studies showed increased skin colonization
(OR 18.86; 95 % confidence interval [CI] 2.20–161.99).
Three out of the five studies that reported on nasal coloniza-
tion showed significant ORs varying from 1.73 (95 % CI
1.16–2.58) to 14.64 (95 % CI 2.82–75.95). For acne one of
the three studies that evaluated skin colonization reported a
significant OR of 4.16 (95 % CI 1.74–9.94). A relation be-
tween nasal colonization and acne was not found. Limitations
in study design and low sample sizes should be taken into
consideration when interpreting the results. Colonisation with
S. aureus seems to be increased in patients with psoriasis. This
bacterial species, known for its potential to induce long-lasting
inflammation, might be involved in psoriasis pathogenesis.
Information on acne is limited. Prospective controlled studies
should further investigate the role of S. aureus in chronic
inflammatory skin diseases.
Introduction
The inflammatory skin disorders atopic dermatitis, psoriasis,
acne and rosacea have been associated with imbalances of the
skin microbiome [1–4]. Local expansion of microbes with
enhanced inflammatory potential, such as Staphylococcus
aureus, was described as a potential mechanism for
(secondary) inflammation in skin diseases [1]. In atopic
dermatitis, patients are more likely to be colonized with
S. aureus than healthy controls and colonization increases
with AD severity [5]. Recent studies suggest that S. aureus
contributes to long-lasting cutaneous inflammation in AD via
binding to Toll-like receptor (TLR) 2 and local immunosup-
pression favoring prolonged colonization. This raises the
question whether S. aureus might also play a role in other
chronic inflammatory skin conditions, such as psoriasis, acne
and rosacea [6].
Current research into the microbial pathogenesis of pso-
riasis focusses mainly on Streptococci. Propionibacterium
acnes is most described in acne and Demodex mites are
linked to rosacea [7–10]. However, the exact role of these
microbes in the diseases is debated. In psoriasis, lesional
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skin is enriched in Streptococcus spp. [11]. However, evi-
dence for the induction of the disease by a preceding strep-
tococcal infection exist only for the subtype of guttate pso-
riasis [12]. S. aureus has been linked to exacerbations in
psoriasis [7, 13]. It can activate Th1 and Th17 cells, pro-
moting the production of interleukins TNF-α and IFN-γ
which perpetuates kerat inocyte damage [14–18].
Furthermore, staphylococcal enterotoxins can activate T
cells inducing a more systemic immunological response,
and staphylococcal peptidoglycan can favour proliferation
of keratinocytes [19–22].
In acne, Propionibacterium acnes probably contributes
to inflammation via stimulation of TLR2 [23–26].
However, certain strains rather than the entire species
seem to be involved and the association between coloni-
zation and acne symptoms has been contested [27–29].
Chitin released from Demodex mites is thought to stimu-
late TLR2 receptors in rosacea [8, 9, 30, 31]. A role for
S. aureus in acne and rosacea can be hypothesized based
on S. aureus’ ability to stimulate TLR2, for example via
alpha toxin [32–34].
Currently, antibiotics are part of standard therapy against
acne and rosacea. Antibiotics often display broad spectrum
activity which could damage the skin [35–37]. Furthermore,
resistance against antibiotics is increasing, putting pressure on
the (maintenance) treatment of inflammatory skin diseases
[38–41]. In the development of new antimicrobial therapies,
targeted treatment directed against a single bacterial species is
gaining in importance [42]. In order to determine the scope of
these new therapeutics we have to understand which specific
microbes play a role in diseases. Investigating the abundance
of S. aureus in a disease-specific ecosystem might give more
insight in its possible role in pathogenesis. This systematic
review and meta-analysis evaluates colonization of the skin
and mucosa with S. aureus in patients with psoriasis, acne and
rosacea compared with healthy controls.
Materials and methods
Type of study
Original experimental and observational (human) studies were
included. Case reports were excluded. No restrictions were
made as to publication date and language.
Type of participants
Studies conducted in patients with psoriasis, acne or rosacea
as diagnosed by a physician, were included. No restriction
was made as to age of the patients.
Type of outcome measures
The primary outcomes were proportion of patients with pres-
ence of S. aureus on the skin, nares or pharynx and the odds
for colonization compared with healthy controls. The second-
ary outcome was presence of S. aureus virulence factors on
the skin or encoded in the bacterial genome. In case of inter-
vention studies, both pre- and post treatment measurements
were included in this review, but only the baseline measure-
ment was included in the meta-analysis. When studies report-
ed multiple measurements over time taken from the same skin
site (without treatment regimen) or when multiple locations
were sampled at the same time point, the mean was included
in the meta-analysis. Articles that reported combined results of
different sample locations were excluded.
Search strategy
The search was conducted in Embase, Medline, Ovid-SP,
Pubmed, Web of Science and the Cochrane Central
Database from inception to September 2014 (Table S1). A
cross reference check was performed to identify further rele-
vant studies.
Study selection and data extraction
The titles and abstracts were screened for relevance and se-
lected on the basis of the in- and exclusion criteria. The quality
of the articles was rated using an extended version of the
Newcastle Ottawa Scale (NOS) (Supplementary material)
[43, 44]. Uncontrolled studies could reach a maximum score
of 7 points for study quality on the NOS. Studies including a
control group could reach a maximum score of 8. Using a
scoring algorithm (Supplementary material), the controlled
articles were classified as being of poor, fair or good quality
[45]. Study selection and quality assessment were performed
independently by two researchers (JT and WF). Disagreements
were discussed and resolved. If identical populations were
described in different publications (co-publication of same
study), the study providing the most data was included.
Statistical analysis
A weighted prevalence of colonization with S. aureus in the
nose and/or skin was calculated. In controlled studies, the
prevalence of colonization was compared between patients
and controls and expressed as an odds ratio with a 95 % con-
fidence interval. If possible, a meta-analysis was carried out
using a random-effects model. Only studies in which patients
were not receiving treatment were included for meta-analysis.
Heterogeneity was assessed using the I2 statistic. If heteroge-
neity was<80 %, data were pooled. The low number of stud-
ies did not permit an assessment of publication bias using
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funnel plots and Egger’s regression [46]. All statistical analy-
ses were performed using Comprehensive Meta-Analysis
Version 2.2 (Biostat, Englewood, NJ). This systematic review




The search yielded a total of 3,791 articles. After
deduplication 2,343 articles remained. Based on title and ab-
stract we identified 51 references on psoriasis, 52 on acne and
seven on rosacea (Fig. 1). Twenty-eight references, 15 about
psoriasis and 13 about acne, met our inclusion criteria after
reading the full text. All studies had an observational study
design. No study in patients with rosacea met our inclusion
criteria. Methods to collect and identify S. aureus and study
characteristics are described in Table S2a and S2b.
Quality of the studies
We rated the quality of the included articles with a control
group as fair (n = 6) and poor (n = 6). The quality of the
uncontrolled studies varied from 0 to 6 points of 7 on the
NOS. Table S3a and S2b describe the NOS scores per study.
The main reason for downgrading the quality of controlled
studies was incomparability of the patient and control groups.
Reasons for downgrading the uncontrolled studies were lim-
ited description of the methods used for collection of bacteria
and identification of S. aureus. Low NOS scores are also part-
ly due to inclusion of abstracts, describing limited information
on methods. Selection bias might have occurred as the studies
included in the review often concern a very specific disease
population (treated mostly in tertiary centres). Furthermore,
the impact of exposures such as treatment regimen at the mo-
ment of collection was poorly reported, which might have
resulted in performance bias.
Colonization with S. aureus of skin and mucosae
in psoriasis
Eight of the 15 studies about psoriasis examined S. aureus on
lesional skin. The proportion of patients with S. aureus on
lesional skin varied from 0.03 (95 % CI 0.02–0.06) to 0.64
(95%CI 0.50–0.76) (Table 1). Three of these studies included
a control group and one showed a significant increase of col-
onization of the skin in patients compared to controls (odds
ratio [OR] 18.86; 95 % CI 2.20–161.99).
Fig. 1 Flow chart of search
strategy and study selection
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Non-lesional skin was examined in six studies. The preva-
lence of patients with colonization varied between 0.06 (95 %
CI 0.02–0.13) and 0.55 (95 % CI 0.42–0.67) (Table 1). The
two studies that included a control group did not find a statis-
tically significant difference in colonization between psoriatic
patients and healthy controls (Tabatabaei 2011; OR 3.13;
95 % CI 0.31–31.14 and Ryu 2003; OR 1.04; 95 % CI
0.31–3.56) [48, 50].
Seven studies evaluated nasal colonization with the pro-
portion of patients with nasal colonization varying from
0.27 (95 % CI 0.13–0.49) to 0.76 (95 % CI 0.62–0.86)
(Table 2). Five studies included a control group of which
three reported a statistically significant increased nasal col-
onization rate in patients with psoriasis compared to
healthy controls. ORs varied from 1.73 (95 % CI 1.16–
2.58) to 14.64 (95 % CI 2.82–75.95) (Table 2).
A meta-analysis was not performed as the treatment regi-
men was not adequately described or differed between the
studies.
Three studies measured S. aureus colonization in the phar-
ynx. The proportion of patients with pharyngeal colonization
was 0.04 (95 % CI 0.03–0.07) (Noah 1990), 0.50 (95 % CI
0.30–0.70) (Ajib 2005) and 0.20 (95 % CI 0.13–0.29)
(Sayama 1998)) [52, 53, 59]. The presence of S. aureus toxins
was investigated in seven studies. An overview of the results
of these studies can be found in Table S4. Balci et al. conclud-
ed that psoriatic patients were colonized with toxigenic strains
more frequent than controls (p=0.006) [13]. Ajib et al. and
Tabatabaei et al. also show data that support a role of toxins in
lesions but no statistically significant difference between pa-
tients and controls was reported [48, 59]. Tomi et al. found a
statistically significant relation between a higher Psoriasis
Table 1 Event rates and odds ratios of skin colonization with S. aureus in psoriatic patients and controls

















Atefi et al. 2012 [19] 40 0.08 (0.02–0.21) 40 0.03 (0.00–0.16) 3.16 (0.32–31.78)
Tabatabaei et al. 2011 [48] 50 0.06 (0.02–0.17) 50 0.02 (0.00–0.13) 3.13 (0.31–31.14)
Balci et al. 2009 [13] 50 0.64 (0.50–0.76) 0.14 (0.07–0.27)
Tomi et al. 2005 [49] 25 0.44 (0.26–0.63) 25 0.04 (0.01–0.24) 18.86 (2.20–161.99)




Brook et al. 1999 [51] 28 0.54 (0.35–0.71)
Sayama et al. 1998 [52] 100 0.15 (0.09–0.23) 0.06 (0.02–0.13)b
Noah et al. 1990 [53] Overall c 297 0.03 (0.02–0.06)
Axilla 297 0.01 (0.00–0.03)
Submammary 297 0.01 (0.00–0.03)
Umbilical 297 0.02 (0.01–0.05)
Inguinal 297 0.02 (0.01–0.05)
Gluteal 297 0.10 (0.07–0.14)
Vaginal 297 0.03 (0.01–0.05)
Penis-scrotal 297 0.04 (0.02–0.07)
Weissmann et al.
1980 [54]
Overall d 10 0.55 (0.42–0.67)
Arm before treatment 10 0.50 (0.22–0.78)
Back before treatment 10 0.60 (0.30–0.84)
Arm after treatment 10 0.40 (0.16–0.70)
Back after treatment 9 0.33 (0.11–0.66)
Aly et al. 1976 [55] 40 0.20 (0.10–0.35) 0.13 (0.05–0.27)
a Sample size is 21
b Sample size is 89
c Average event rate of the different locations on the skin
d Average event rate of multiple locations on the skin before treatment
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Area Severity Index (PASI) score and enterotoxin-positive
S. aureus versus toxin negative S. aureus (p=0.001) [49].
Colonization with S. aureus of skin and mucosae in acne
Seven of the 13 articles evaluating acne patients reported
on lesional skin colonization with S. aureus . The
proportion of patients with skin colonization varied
between 0.01 (95 % CI 0.00–0.07) and 0.54 (95 % CI
0.40–0.67) (Table 3). Three studies compared skin coloni-
zation between patients and controls. Only one found a
significant OR of 4.16 (95 % CI 1.74–9.94) (Table 3) [60,
62, 65]. Seven studies reported on the prevalence of nasal
S. aureus colonization (Table 4). Pooled analysis from the
Table 2 Event rates and odds
ratios of nasal colonization with
S. aureus in psoriatic patients and
controls









Event rate of nasal
colonization
(95 % CI)
Andersen et al. 2013
[56]
112 0.36 (0.28–0.45) 1985 Not mentioned 1.73 (1.16–2.58)
Balci et al. 2009 [13] 50 0.50 (0.36–0.64) 50 0.34 (0.22–0.48) 1.94 (0.87–4.35)
Tomi et al. 2005 [49] 25 0.56 (0.37–0.74) 25 0.08 (0.02–0.27) 14.64 (2.82–75.95)
Ryu et al. 2003 [50] 22 0.27 (0.13–0.49) 25 0.24 (0.11–0.44) 1.18 (0.32–4.40)
Klein et al. 1997 [57] 33 0.33 (0.19–0.51)
Singh et al. 1978 [58] 50 0.76 (0.62–0.86) 33 0.6 (0.43–0.75) 2.64 (1.03–6.79)
Aly et al. 1976 [55] 40 0.30 (0.18–0.46)
Table 3 Event rates and odds ratios of skin colonization with S. aureus in acne patients and controls


















Numata et al. 2013 [60] 100 0.01 (0.00–0.07)a 100 0.01 (0.00–0.07)a
Moon et al. 2012 [61] 100 0.06 (0.03–0.13)
Hassanzadeh et al. 2008 [62] 100 0.41 (0.32–0.51) 100 0.30 (0.22–0.40)b 1.62 (0.90–2.91)
Williams et al.
1992c [63]
Before treatment 28 0.02 (0.00–0.22)a
1 month after start 28 0.14 (0.05–0.32)
2 months after start 28 0.32 (0.18–0.51)
3 months after start 28 0.21 (0.10–0.40)
4 months after start 28 0.25 (0.12–0.44)
5 months after start 28 0.02 (0.00–0.22)a
Al Mishari et al.
1987d [35]
Before treatment 20 0.05 (0.01–0.28) 0.05 (0.01–0.28)
4 months after start 20 0.02 (0.00–0.29)a
Leyden et al.
1986e [64]
Before treatment 40 0.03 (0.00–0.16)
1 month after start 40 0.15 (0.07–0.30)
5 months after start 40 0.50 (0.35–0.65)
Batova et al.
1971 [65]
Swab without buffer 40 0.15 (0.07–0.30)
Swab with buffer 50 0.54 (0.40–0.67) 50 0.22 (0.13–0.36) 4.16 (1.74–9.94)
a Event rate = 0.00 (OR not calculated)
b Healthy skin of patients is used as a control
c Patients were treated with isotretinoin for 4 months
d Patients were treated with tetracycline for 4 months
e Patients were treated with isotretinoin for 5 months
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five studies in which patients were not on antimicrobial
treatment (324 patients) showed a nasal colonization rate
of 0.08 (95 % CI 0.03–0.20) (Fig. 2). With an I2 of 71 %,
heterogeneity was considered to be moderate. Two studies
included a control group but did not demonstrate a statisti-
cally significant difference in S. aureus nasal colonization
rates between patients and healthy controls [66, 69]. Basak
et al., Fanelli et al. and Levy et al. found pharyngeal colo-
nization rates of 0.09, 0.33 and 0.26, respectively [67, 70,
71]. No studies reported on the relation between severity of
acne and colonization with S. aureus or presence of
S. aureus virulence factors.
Discussion
In this systematic review 28 observational studies comprising
1,880 patients were included to evaluate skin and mucosal
colonization in patients with psoriasis, acne and rosacea.
Patients with psoriasis seem to be colonized with S. aureus
in the nose more often than healthy controls. One study shows
an increased risk of skin colonization in patients compared
with controls. However, the sample size of this study was
rather small (n=25) [49]. The literature about virulence fac-
tors in psoriatic patients versus controls is ambiguous. Only
one study reported about disease severity in relation to
Table 4 Event rates and odds ratios of nasal colonization with S. aureus in patients with acne patients and controls
Author Patients Controls Odds ratio
Sample size Event rate of nasal
colonization (95 % CI)
Sample size Event rate of nasal
colonization (95 % CI)
Ozuguz et al. 2014a [66] Before treatment 55 0.01 (0.00–0.13)e 20 0.02 (0.01–0.29)e
3 months after start 55 0.09 (0.04–0.20)
Basak et al. 2013b [67] Before treatment 35 0.09 (0.03–0.23)
After treatment 35 0.40 (0.25–0.57)
Toyne et al. 2012 [68] 116 0.26 (0.19–0.35)
Khorvash et al. 2012 [69] 166 0.22 (0.16–0.29) 158 0.27 (0.20–0.34) 0.77 (0.46–1.29)
Fanelli et al. 2011 [70] 83 0.19 (0.12–0.29)
Williams et al. 1992c [63] Before treatment 28 0.11 (0.03–0.28)
1 month after start 28 0.32 (0.18–0.51)
2 months after start 28 0.57 (0.39–0.74)
3 months after start 28 0.46 (0.29–0.64)
4 months after start 28 0.32 (0.18–0.51)
5 months after start 28 0.43 (0.26–0.61)
Leyden et al. 1986d [64] Before treatment 40 0.03 (0.00–0.16)
1 months after start 40 0.30 (0.18–0.46)
5 months after start 40 0.70 (0.54–0.82)
a Twenty patients were treated with oral antibiotics, 20 with isotretinoin, 15 patients received no treatment
b Twenty patients were treated with isotretinoin for an unknown duration
c Patients were treated with isotretinoin for 4 months
d Patients were treated with isotretinoin for 5 months
e Event rate = 0.00 (OR not calculated)
Fig. 2 Forest plot of studies
reporting proportions of acne
patients with nasal S. aureus
colonization receiving no
treatment at the time of sampling.
I2 = 71
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S. aureus and found a statistically significant relation between
a higher PASI score and enterotoxin-positive S. aureus versus
toxin negative S. aureus. In studies on acne, an association
between skin colonization and the disease was only found in
one of the three articles and therefore less evident [60, 62, 65].
In almost one tenth of the patients with acne S. aureus was
present in the nose. This is low compared with the nasal col-
onization rate of healthy people (around 25%) [72]. Although
the patients included in the meta-analysis did not use treatment
at the time of sampling, the low colonization rates might be
due to a long-term effect of former use of antibiotics [70, 71].
Two studies compared nasal colonization in acne patients with
healthy controls and found no statistically significant differ-
ence. It has to be noted that in all of these studies there were
only few discussions on whether the presence of S. aureus
represented clear colonization or whether the bacteria were
causal agents of pathogenicity. No studies could be included
that assessed S. aureus colonization in patients with rosacea.
Also in current review literature S. aureus is not implicated in
the pathophysiology of rosacea [9]. Limitations in study de-
sign, such as incomparability of patient and control groups, as
well as indirectness and imprecision due to low sample sizes,
rate the quality of the evidence down and should be taken in
consideration when interpreting the results. Essential informa-
tion about factors that influence microbiota such as treatment
regimen, the exact skin site where a sample was taken and
duration of the disease which might influence the antimicro-
bial effect of the host immune response, was often missing.
This hampered our ability to draw conclusions about the bac-
terial ecology of the skin [73–75].
Few studies performed a pre- and post treatment analysis of
S. aureus abundance.Weissmann et al. described a decrease in
the percentage of colonized psoriasis patients from 55 % to
36 % after PUVA (photochemotherapy) [54]. Three studies
reported an increase of S. aureus colonization of nose, oro-
pharynx and skin after isotretinoin therapy for acne (of which
one was statistically significant), whereas Ozuguz et al. found
no change [63, 64, 66, 67]. In cross-sectional studies Fanelli et
al. and Levy et al. demonstrated that antibiotic use decreased
the prevalence of S. aureus nasal and oropharyngeal coloni-
zation [70, 71]. However, an increase of S. aureus coloniza-
tion was seen after tetracycline therapy in Ozuguz et al [66].
None of the above-mentioned studies reported on the relation
between changes in S. aureus density and clinical symptoms
which could give important information with respect to
S. aureus causality.
This review has some limitations. Determining the preva-
lence of S. aureus colonization was not the primary objective
in a substantial part of the studies. Therefore, indirectness of
the evidence with regard to the population might have oc-
curred. Some studies comprised small sample sizes resulting
in effect estimates with wide confidence intervals. Controlled
studies did not adjust for confounders, such as age, which
might influence the given odds ratio. There is a possibility
of publication bias as only published studies were considered
and as literature focuses on just a few of the many toxins that
S. aureus produces, this review provides a limited insight on
the correlation between toxins of S. aureus and psoriasis and
acne.
Future research should have a more longitudinal character
and focus on bacteria as part of an ecosystem related to sever-
ity. This might give more insight in the cause–consequence
relation between microorganisms and disease. It is important
to consider that the capacity of a microbe to promote disease
also depends on other factors such as the host’s genetic pre-
disposition, skin barrier integrity and the coexistence of other
microbes. As S. aureus is common at all depths of the skin,
biopsies might be of additional value next to the techniques
that evaluate the superficial skin [76]. Molecular approaches
to analyse these samples will give a more complete picture of
the microbial diversity facilitating the evaluation of low abun-
dance species and their influence [37, 74].
This systematic review summarises all available data on
S. aureus colonization and the presence of virulence factors
on the skin and mucosa of patients with psoriasis and acne.
Patients with psoriasis seem to be colonized with S. aureus
more often than healthy controls. The overabundant S. aureus
in the microbiome of psoriasis patients might play a role in
perpetuating chronic inflammation. For patients with acne a
relation between colonization and the disease was less evident
and for rosacea no information about colonization could be
obtained from the literature. Determining the presence of in-
dividual bacterial species with inflammatory potential, includ-
ing S. aureus, in patients compared with controls is a first step
towards elucidating their possible role in skin diseases and
might lead to new options for more targeted antimicrobial
therapy.
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